Introduction
Asthma has recently been recognized as an umbrella term that encompasses various phenotypes and endotypes rather than a single disease. 1, 2 Despite the diversity of endotypes and inflammatory patterns, 3 type-2/eosinophilic inflammation remains a key driver in nearly half of all patients with asthma 4 and has been demonstrated in airway epithelial cells isolated from patients with mild-to-moderate asthma. 5 Therefore, efforts to develop noninvasive biomarkers for type-2/eosinophilic airway inflammation have been made during this decade. Currently, fraction of exhaled nitric oxide (FeNO) and serum periostin levels are considered biomarkers of type-2/eosinophilic inflammation. In the present review article, the strength and weakness of FeNO and serum periostin levels as markers of type-2 inflammation are briefly summarized, which may facilitate improved interpretation of markers in the management of asthma. Studies that compared the utility of two markers to identify severe type-2/eosinophilic airway inflammation or to diagnose pediatric asthma are also reviewed. A singlemarker approach may be insufficient to cover the whole range of asthma management, from disease diagnosis to prediction of disease prognosis and response to treatments, even when limited to the prediction of eosinophilic airway inflammation. 6 However, evidence regarding the use of a multiple-marker approach to identify severe type-2/eosinophilic asthma is scarce. 7, 8 Herein, the potential utility of a composite marker of FeNO and serum periostin levels is presented based on a sub-analysis of the Kinki Hokuriku Airway disease Conference (KiHAC). Geno-endo-phenotypes with either high FeNO levels only or serum perisotin levels only are also described.
FeNO
Currently, FeNO is commonly used in the clinical settings of asthma, and the measurement of FeNO at 50 mL/s of expiratory flow using NIOX VERO ® and NObreath ® is generally accepted by health insurance systems, including in Japan. 9 The utility of this marker in 29 Although the precise mechanisms are unknown, elevated serum periostin levels are less frequently observed in obese patients with asthma, 43 which is also reported in a recent epidemiological study on serum periostin levels. 44 Possibly reflecting its fibrosis-prone nature, 45 serum periostin levels are elevated in fibrotic diseases, such as idiopathic interstitial pneumonia 46 and scleroderma 47 ( Table 1) .
Comparisons between FeNO and serum periostin in the prediction of airway eosinophilia and diagnosis of pediatric asthma
Efforts to identify the best single marker with sufficient sensitivity and specificity to predict airway eosinophilia is clinically important. Although direct comparisons between FeNO levels and serum periostin levels are rarely reported (Table 2) , serum periostin levels have been found to be the best predictor of airway eosinophilia among FeNO, blood eosinophil counts, serum IgE, and serum periostin in adult patients with severe asthma who remained symptomatic despite receiving high doses of ICS treatment (BOBCAT study) (n ¼ 67; 32 males; mean age, 46 years; FEV 1 , 60%; daily ICS doses >1000 mg fluticasone propionate equivalent; Asthma Control Questionnaire score, 2.7). 41 These results were not observed in another study of patients with mild-to-moderate asthma (n ¼ 110; 54 males; mean age, 49 years; FEV 1 , 100%; daily ICS doses, 500 mg fluticasone propionate equivalent). 48 However, the potential mechanisms underlying this discrepancy may be attributable to differences in periostin assay systems and disease severity among studied patients. 49 A recent study of Japanese pediatric patients with asthma reported a similar predictability of serum periostin and FeNO in distinguishing children with asthma from controls. 50 Thus, results from a single-marker approach may often depend on patient characteristics and the periostin assay kits used. Thus, a multiple-marker approach is expected to improve the accuracy in predicting severe type-2/eosinophilic asthma.
Combination of FeNO and serum periostin in the management of severe asthma
In several diseases, such as pancreatic adenocarcinoma, 51 Alzheimer's disease, 52 and severe graft-versus-host disease, 53 the superiority of a multiple-marker approach in terms of diagnostic accuracy over a single-marker approach has been reported. In mildto-severe asthma, combinations of FeNO levels, blood eosinophil counts, and serum total IgE levels demonstrated no greater utility in predicting airway eosinophilia in asthma than single markers. 54 However, no studies of a composite marker of FeNO and serum periostin in predicting severe eosinophilic asthma have been reported. In a sub-analysis of the Kinki Hokuriku Airway disease Conference (KiHAC) study, the utility of a composite marker of high FeNO and high serum periostin levels were examined. FeNO levels at a constant exhalation flow rate of 50 mL/s were measured using a equivalent to fluticasone propionate; patients with history of more than 10 pack-years were excluded) were stratified into four groups according to FeNO levels (cutoff value, 25 ppb) and serum periostin levels (cutoff value, 95 ng/mL). For the convenience of understanding, patients with low FeNO and low serum periostin levels were categorized as group A (n ¼ 39); high FeNO and low serum periostin levels as group B (n ¼ 34); low FeNO and high serum periostin levels as group C (n ¼ 25); and high FeNO and high serum periostin levels as group D (n ¼ 23) (Fig. 1) .
To focus on the role of serum periostin in high FeNO levels (!25 ppb), the clinical aspects of groups B and D were first compared in our previous study. 55 Patients in group D (n ¼ 23) received more intensive treatment, had a history of asthma admission, and a decline in FEV 1 of !30 mL per year more frequently than those in group B (Table 3 ). Adherence to medications was not different between groups B and D (P ¼ 0.56). Despite receiving intensive treatment, patients in group D had frequent asthma exacerbations that required systemic corticosteroid treatment over 2 years following enrollment ( Fig. 2) and had an odds ratio of approximately 3 compared with the patients in groups A, B, and C (n ¼ 97, one patient in group C was lost to follow-up), even after adjustment for airflow limitation (FEV 1 < 80% of predicted) and an episode of asthma exacerbation in the past 6 months. To examine if this endo-phenotype of severe type-2 inflammation was genetically associated, we examined the frequency of the GG genotype of IL4RA rs8832. This variant was identified in a pharmacogenetics study of pitrakinra, an inhibitor of IL-4 receptor a that is a common sub-chain for both IL-4 and IL-13 signaling, as a genetic marker of good responses to pitrakinra. 56 As expected, patients in group D had a higher frequency of the GG genotype of IL4RA rs8832 (35%) than the remaining patients (15%) in groups A, B, and C (Fig. 3a) . Thus, high levels of both FeNO and serum periostin may identify patients with severe type-2/eosinophilic inflammation, potentially activated via IL-4 receptor a.
Next, geno-endo-phenotypes of patients with high FeNO levels only, high serum periostin levels only, or low levels of both are addressed ( Table 3 ). The GG genotype of POSTN rs3829365 that was associated with elevated serum periostin levels 34 was the least frequent in group A (low levels of both FeNO and periostin; Fig. 3b ), which was characterized by low blood eosinophil counts. A lack of elevation in type-2/eosinophilic markers may indicate genetically different backgrounds in certain patients with asthma. The frequencies of the GG genotype of POSTN rs3829365 were similar in groups B (high FeNO levels only) and C (high periostin levels only). The mechanism underlying the lower serum periostin levels in group B than in group C despite a similar frequency of the GG genotype of POSTN rs3829365 in the two groups remains unknown. Larger studies on the association between serum periostin levels and genetic background including POSTN and IL4RA would be required. Patients in group B had a significantly lower frequency of history of admission due to asthma (Fig. 3c ) and were taller (Fig. 3d ) than those in group C, while group C was characterized by the Fig. 1 . Stratification of patients into four groups according to FeNO (<25 ppb, low; !25 ppb, high) and serum periostin levels (<95 ng/mL, low; !95 ng/mL, high). longest disease duration (Fig. 3e) and ICS-untreated period, with a gap of approximately 10 years among the four groups. Lastly, even when the cutoff value of FeNO was set at 40 ppb for analysis, this level was shown to be appropriate to identify patients with poorly controlled asthma 57 and patients with treated asthma with a more rapid decline in FEV 1 . 23 The following aspects of the four groups remained significantly different: higher frequencies of the Global Initiative for Asthma (GINA) treatment step 5, subsequent asthma exacerbations, and more rapid declines in group D than in group B; taller and lower frequencies of history of admission due to asthma Fig. 2 . Frequency of asthma exacerbations over 2 years following enrollment in patients belonging to the four groups stratified according to FeNO and serum periostin levels. in group B than in group C; the longest disease duration and ICSuntreated period in group C; the least frequent GG genotype of POSTN rs3829365 in group A; and the highest frequency of the GG genotype of IL4RA rs8832 in group D (data not shown). Conclusively, high levels of both FeNO and serum periostin may reflect severe type-2/eosinophilic airway inflammation. However, each biomarker has specific characteristics and modifiers; patients with either high FeNO or serum periostin levels only should be treated with ICS but may not necessarily require as intense treatment as patients with high levels of both markers.
Conclusions
Because patients with severe eosinophilic inflammation do not always complain of symptoms of asthma, 58, 59 the identification of patients at risk of asthma exacerbations and pulmonary function decline is clinically important. The use of a composite marker of FeNO and serum periostin levels may have utility in achieving this goal. duration of asthma in the four groups, stratified according to FeNO and serum periostin levels. In (c)e(e), P < 0.05 was considered significant for comparison between B and C, which was our main interest; using the Bonferroni correction, P < 0.01 was considered significant for comparison between the other two groups. In one patient in group C, the same patient who was lost to follow-up, variants of IL4RA and POSTN genes could not be analyzed because of insufficient DNA quality.
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